Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported new equity awards. On February 2, 2026, he received 99,100 restricted stock units, each representing one share of Aclaris common stock. These RSUs vest in four equal annual installments starting on the first anniversary of February 2, 2026, conditioned on his continued service.
He was also granted an employee stock option for 346,800 shares of common stock at an exercise price of $3.61 per share. The option becomes exercisable as 25% of the shares vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continued service.
Aclaris Therapeutics Chief Business Officer James Loerop reported routine equity compensation activity. On February 3, 2026, 20,875 restricted stock units were converted into an equal number of Aclaris common shares. Each restricted stock unit represents the right to receive one share of common stock.
To cover tax withholding on this vesting, the issuer withheld 5,937 common shares at $3.47 per share, reported under transaction code F. After these transactions, Loerop directly owned 192,260 shares of common stock and 62,625 restricted stock units, which continue to vest in four equal installments on the first four anniversaries of February 3, 2025, subject to continuous service.
Aclaris Therapeutics CEO Walker Neal reported equity compensation activity involving restricted stock units and common stock. On February 3, 2026, 63,475 restricted stock units were converted into 63,475 shares of common stock at an exercise price of $0.
To cover tax withholding related to this vesting, 18,611 shares of common stock were withheld by the company at a price of $3.47 per share. After these transactions, Neal directly owned 1,543,886 shares of common stock and 190,425 restricted stock units, which vest in four equal annual installments starting on February 3, 2025, subject to continuous service.
Aclaris Therapeutics President and COO Hugh M. Davis reported an equity compensation transaction involving restricted stock units (RSUs). On February 3, 2026, 18,675 RSUs converted into 18,675 shares of Aclaris Therapeutics common stock at an exercise price of $0 per share.
After this transaction, Davis directly owned 45,425 shares of common stock and 56,025 RSUs. Each RSU represents the right to receive one share of common stock. The RSUs underlying this transaction vest in four equal annual installments on the first through fourth anniversaries of February 3, 2025, subject to his continuous service.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity. On February 3, 2026, 22,025 restricted stock units converted into an equal number of common shares at an exercise price of $0. To cover tax withholding on this vesting, 6,449 common shares were withheld by the company at $3.47 per share.
After these transactions, Balthaser directly owned 185,755 shares of common stock and 66,075 restricted stock units, which continue to vest in four equal annual installments starting from February 3, 2025, contingent on his continued service.
Aclaris Therapeutics, Inc.'s Chief Business Officer reported multiple equity compensation events on February 1, 2026. Several restricted stock unit (RSU) awards were exercised (transaction code M), delivering 11,250, 7,500, and 14,750 shares of common stock in separate transactions.
The filing also reports a transaction coded F, where 10,686 shares were withheld at $3.51 per share to cover tax obligations tied to RSU vesting. The RSU grants vest in four equal annual installments starting on February 1 of 2022, 2023, and 2024, subject to continued service. This amendment corrects a prior filing that mistakenly referenced a February 1, 2025 transaction due to a filing platform error.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported routine equity compensation activity involving restricted stock units and common stock. On February 1, 2026, 14,750 restricted stock units were converted into an equal number of shares of Aclaris common stock, reflecting previously granted equity awards.
To cover related tax withholding on this vesting, the issuer withheld 4,984 shares of common stock at $3.51 per share. Following these transactions, Balthaser directly held 170,179 shares of common stock and 29,500 restricted stock units. The remaining restricted stock units vest in four equal annual installments beginning on the first anniversary of February 1, 2024, contingent on his continued service.
Aclaris Therapeutics Chief Business Officer James Loerop reported an automatic share withholding related to equity compensation. On February 1, 2025, the issuer withheld 15,980 shares of common stock at $2.48 per share to cover his tax obligations upon restricted stock unit vesting.
After this transaction, Loerop beneficially owned 102,773 shares of Aclaris common stock in direct ownership. The filing is an amendment that corrects the previously reported number of shares withheld, which will change the reported beneficial ownership amounts in later filings.
Aclaris Therapeutics’ chief business officer filed an amended insider share report to correct how many shares were withheld for taxes on vested restricted stock units. On 02/01/2025, the company withheld 15,980 shares of common stock at $2.48 per share to cover tax obligations. After this correction, the officer directly held 102,773 shares of Aclaris common stock. The amendment clarifies the prior disclosure and will adjust reported beneficial ownership in future filings.
BlackRock, Inc. filed an amended Schedule 13G reporting a sizable passive stake in Aclaris Therapeutics, Inc. common stock. As of the event date of 12/31/2025, BlackRock reported beneficial ownership of 6,700,629 Aclaris shares, representing 6.2% of the outstanding common stock.
BlackRock reported sole voting power over 6,626,227 shares and sole dispositive power over 6,700,629 shares, with no shared voting or dispositive power. The filing notes that various underlying clients or shareholders have rights to dividends or sale proceeds, but no individual person has more than five percent of Aclaris’s total outstanding common shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Aclaris, consistent with a passive institutional investment position.